Call IVLVNAC / acetylcysteine / PubChem CID 12035
A thiol-containing cysteine derivative with an FDA-labeled lifesaving use, established mucolytic chemistry, and positive human trials across respiratory, behavioral, inflammatory, reproductive, and hepatic research.
Outcomes are stated as studied: population, route, comparator, and measured endpoint. The result—not a generalized wellness promise—is the claim.
Evidence levels: 1 established clinical use or human pharmacology2 positive randomized human evidence3 promising, limited, or mixed human evidence4 mechanistic or biomarker signal
Acetylcysteine · emergency treatment
N-acetylcysteine restores cysteine availability and hepatic glutathione, allowing detoxification of the reactive metabolite NAPQI. This is a time-sensitive, FDA-labeled use and one of clinical toxicology’s foundational antidote pathways.
Established human biochemistry · route and dose matter
NAC functions as a cysteine reservoir through deacetylation and thiol-exchange chemistry. Cysteine then enters the two ATP-dependent steps that synthesize reduced glutathione, a central intracellular redox buffer and enzyme substrate.
NAC · adults with frequent bronchiectasis flares
In the 161-person BENE randomized trial, 600 mg twice daily for 12 months reduced exacerbations from 1.98 to 1.31 per patient-year. Sputum volume fell, quality of life improved, and severe adverse events were not reported in the NAC group.
NAC · adjunct during steroid taper
A double-blind trial of 168 patients recorded 6 relapses with NAC versus 19 with placebo over 22 weeks. Endoscopic relapse and inflammatory markers also favored NAC when used alongside mesalamine and a steroid taper.
NAC · pediatric randomized trials
A placebo-controlled pilot produced a large reduction in irritability scores, and two adjunct-to-risperidone trials also favored NAC for irritability. The measured benefit was behavioral irritability—not a claim to alter autism’s core features.
NAC · adults with excoriation disorder
In a randomized 66-adult trial, 47% receiving NAC were much or very much improved versus 19% receiving placebo. Both the modified Yale–Brown scale and clinician severity ratings favored NAC.
NAC · adult trichotillomania
A 12-week trial found 56% of adults were much or very much improved with NAC versus 16% with placebo, with separation emerging after week 9. A pediatric trial was negative, making age and phenotype important variables.
NAC · men with infertility
Randomized evidence reports improvements in sperm concentration, motility, and morphology, with additive effects when NAC was paired with selenium. A later five-study meta-analysis also favored NAC across several semen measures.
Positive one-off studies, mixed clinical programs, and biomarker findings with enough biological or clinical signal to deserve attention and further testing.
NAC · adjunct to clomiphene
A 150-person placebo-controlled trial in clomiphene-resistant PCOS found ovulation rates of 49.3% versus 1.3% and pregnancy rates of 21.3% versus 0% when NAC was added. Comparative trials have produced less decisive results.
NAC · 36-person SLE pilot
Daily NAC at 2.4–4.8 g reduced SLEDAI, selected BILAG scores, and fatigue while suppressing T-cell mTOR activity. This mechanistically rich randomized pilot warrants larger confirmation.
IV NAC · early coma-grade hospital patients
A 173-patient trial found transplant-free survival of 52% with NAC versus 30% with placebo in coma grades I–II. The overall survival endpoint and later pooled results were less conclusive, concentrating the signal in early disease.
NAC · adjunctive psychiatric treatment
Several trials—particularly in bipolar depression—reported symptom and functional improvement. A recent 12-study meta-analysis found a small benefit, although individual larger trials have been negative and heterogeneity remains substantial.
NAC · adjunct to standard OCD medication
Multiple small randomized studies reported lower OCD scores or higher response rates when NAC augmented standard treatment. A larger 20-week phase III study was negative, leaving a credible but mixed clinical signal.
NAC · adolescent cessation treatment
An 8-week adolescent trial found more than twice the odds of a negative urine cannabinoid test with NAC plus incentives and counseling. Adult and later youth studies were negative, indicating that treatment context may determine the signal.
NAC · small NAFLD/NASH studies
Small human trials reported lower ALT and improvements in steatosis, ballooning, or activity scores, including when NAC was combined with metformin. Controlled confirmation with modern imaging and histologic endpoints is needed.
NAC · perioperative protocols
A CABG trial and earlier pooled randomized data reported fewer postoperative atrial-fibrillation episodes. Other controlled cardiac and thoracic-surgery trials were negative, so the effect may depend on procedure, timing, or protocol.
NAC · high-noise exposure studies
Randomized studies and pooled analyses suggest small protective effects at selected frequencies or in selected ears. The primary outcome in a large military trial was not significant, but secondary auditory signals support continued study.
NAC · chronic respiratory disease
Earlier pooled studies found fewer exacerbations in selected chronic-bronchitis and COPD populations. A newer 968-person, two-year trial in mild-to-moderate COPD was negative, pointing to a population- or phenotype-dependent effect.
NAC · 25-person mechanistic trial
A randomized biomarker study found higher antioxidant capacity and granulosa-cell gene-expression changes consistent with reduced apoptosis. Clinical fertility, pain, and live-birth outcomes were not tested.
NAC is not simply “an antioxidant.” It participates in sulfur metabolism, precursor supply, thiol–disulfide exchange, enzymatic redox cycling, and potentially neuromodulatory and transcriptional signaling.
C₅H₉NO₃SHS–CH₂–CH(NH₂)–COOHγ-glutamylcysteineγ-Glu-Cys-Gly2 GSH + ROOH → GSSG + ROH + H₂OGSSG + NADPH + H⁺ → 2 GSH + NADP⁺NAC + H₂O → L-cysteine + acetateDeacetylation and extracellular thiol exchange expand the cysteine pool. Cysteine then enters the two ATP-dependent reactions that synthesize reduced glutathione (GSH).
NAPQI + GSH → non-reactive conjugatesIn acetaminophen toxicity, NAC restores hepatic GSH and can support alternate detoxification chemistry. The pathway has a direct, lifesaving clinical endpoint—not merely a theoretical antioxidant claim.
R–S–S–R′ + NAC–SH ⇌ R–SH + NAC–S–S–R′NAC’s free thiol attacks accessible disulfides. This explains its established mucolytic action on cross-linked mucins and its ability to release or reduce selected protein thiols.
2 GSH + ROOH → GSSG + ROH + H₂OGlutathione peroxidases use GSH to reduce peroxides. Glutathione reductase then uses NADPH to regenerate GSH, making the system catalytic rather than a one-time radical trap.
cystine(out) + glutamate(in) ⇌ cystine(in) + glutamate(out)In preclinical models, cystine–glutamate exchange restores extrasynaptic glutamate tone at inhibitory mGluR2/3 receptors and can dampen cue-triggered synaptic glutamate release. This is a leading mechanism behind NAC research in compulsive behavior and addiction.
NAC → cysteine → H₂S → persulfides / sulfane sulfurCell studies suggest NAC-derived cysteine can generate mitochondrial H₂S and sulfane-sulfur species that mediate rapid cytoprotection. This may explain effects that occur faster than bulk GSH synthesis alone predicts.
Keap1 redox change → Nrf2 stabilization → ARE transcriptionNAC-linked redox and persulfide chemistry may alter Keap1 control of Nrf2, increasing expression of antioxidant and detoxification systems. Evidence is strongest in cells and animal models; human pathway engagement is less fully mapped.
redox state ↔ mTOR / NF-κB / mitochondrial signalingNAC has altered mTOR activity, cytokine-linked pathways, mitochondrial redox, and apoptosis markers in selected human and experimental studies. These are biologically plausible network effects, not a single universal mechanism.